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serum biomarkers in people with 
chronic low back pain and Modic 1 
changes: a case-control study
Margaux Boisson1, Didier Borderie2,3,4, Yves Henrotin5,6, stéphanie teboul-Coré1,  
Marie-Martine Lefèvre-Colau1,7,8,9, François Rannou1,4,7 & Christelle Nguyen1,4,7
We aimed to compare serum biomarkers of inflammation, redox status and cartilage degradation 
between chronic low back pain (cLBP) patients with and without Modic 1 changes. We used a 
convenience sample of patients recruited from a single center, case-control study, conducted in a 
tertiary care center. From December, 2014 to May, 2016, 2,292 patients were consecutively screened, 
34 met inclusion criteria and were prospectively enrolled in the present study. Cases (n = 13) were 
defined as patients with Modic 1 changes detected on MRI and controls (n = 21) as cLBP patients 
without (Modic 0). To assess serum biomarkers of inflammation, redox status and cartilage degradation, 
fasting serum samples were collected in a standardized manner and analyzed by immunoassays and 
spectrophotometry. Mean (95% CI) age was 44.1 (40.0–48.1) years and mean LBP duration was 72.5 
(53.0–91.9) months. Serum biomarkers of inflammation (IL-1β, IL-6, IL-8 and TNF-α), redox status (total 
thiols, advanced oxidation protein products and carbonyl groups) and cartilage degradation (Coll2-1 
and Coll2-1NO2) did not differ between cLBP patients with and without Modic 1 changes. In summary, 
we did not find any differences in serum biomarkers between cLBP patients with and without Modic 1 
changes. Interpretation is limited by convenience sampling and small sample size.
Non-specific chronic low back pain (cLBP) is a common symptom. It is the leading cause of life years lived with 
disability in the world1. The etiological diagnosis of LBP is a challenge because consistent anatomoclinical cor-
relation is lacking. In the late 1980s, elementary changes of vertebral endplate subchondral bone were described 
adjacent to degenerative disc disease on MRI (Modic classification)2. In a subset of chronic LBP patients, Modic 
1 changes on MRI are associated with clinical3,4 and laboratory signs4. This condition is now refered as active 
discopathy5,6.
Patients with cLBP and active discopathy have inflammatory-like LBP and low grade local and systemic 
inflammation5,6, but do not fulfill the classification criteria for spondyloarthropathies3. Consistently, targeting 
local inflammation with intradiscal anti-inflammatory drugs have positive effects on pain at short term7–9. These 
observations suggest that local inflammation could explain in part active discopathy-related symptoms. However, 
effects of anti-inflammatory therapies are not sustained, which suggests that aside from inflammation, other 
elementary molecular pathways may contribute to active discopathy-related symptoms. For example, changes in 
cartilage remodeling have been described during active discopathy and include decreased expression of chon-
drogenesis transcription factors such as type 2 collagen and Sox-910. Some authors also reported an increase in 
oxidative and nitrosative stress markers in patients with active discopathy as compared to those without11.
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We hypothesized that along with inflammation, other elementary molecular pathways including redox status 
and cartilage degradation may be activated in patients with cLBP and active discopathy, and aimed to compare 
serum biomarkers of interest between cLBP patients with and without active discopathy.
Methods
Study design. We used a convenience sample of patients with cLBP with or without active discopathy 
recruited from a previous cross-sectional case-control study performed from December, 2014 to May, 2016, in a 
single tertiary care center (Rehabilitation Department, Cochin Hospital, Paris, France)12. Our study is reported 
in accordance with the Strengthening The Reporting of OBservational Studies in Epidemiology checklist13 (see 
supplementary material).
Participants. All patients referred to our department were prospectively and consecutively screened. 
Patients fulfilling the following inclusion criteria and who agreed to participate were prospectively enrolled in 
the primary study: male sex, age ≥18 and <65 years, Caucasian, cLBP defined as a daily LBP persisting for ≥3 
months, lumbar MRI ≤6 months, lumbar type 1 Modic changes at a single level with preserved intervertebral 
disc height (intervertebral space narrowing <50%, maximal height of the intervertebral disc visually estimated on 
mid-sagittal T2-weighted MRI and described as a percentage of the nearest normal above disc height) for cases, 
and lumbar type 0 Modic changes for controls. Patients were included in the present study if at least one of the 
serum markers of interest could be assessed. A complete description of the inclusion and exclusion criteria was 
published12.
Lumbar MRI. A lumbar MRI with T1-, T2- and Short Tau Inversion Recovery (STIR)-weighted sequences 
≤6 months were qualitatively assessed by 1 investigator (STC) for presence and level of types 0, 1, 2 and 3 Modic 
changes for each patient.
Serum biomarkers. Fasting serum samples were collected at baseline (between 7 and 9 am, before break-
fast and after at least a 48 hr-wash-out of non-steroidal anti-inflammatory drugs, smoking and alcohol con-
sumption) and stored at −40 °C. Protein carbonyl groups were detected and quantified by spectrophotometry 
using 2,4-dinitrophenylhydrazine14. The carbonyl content was expressed as nanomoles of carbonyl per mil-
ligram of proteins. Thiol determinations were based on the thiol/disulfide reaction of thiol and Ellman’s reagent, 
5,5′-dithiobis(2-nitrobenzoic acid)15. Advanced oxidation protein products (AOPP) were quantified as described 
previously16. AOPP concentrations were expressed as micromoles per liter (μmol/L) of chloramine T equivalent. 
Coll2-1, a peptide located in the triple helical part of type 2 collagen molecule, and its nitrated form (Coll2-1NO2) 
were measured by using enzyme-linked immunosorbent assay (ELISA) following the recommendations of the 
manufacturer (Artialis, Liège, Belgium, www.artialis.com) and cytokines (IL-1β, IL-6, IL-8 and TNF-α) by using 
the Meso Scale Discovery array technology (MSD, Rockville, USA).
Statistical methods. For descriptive analyses, qualitative variables were reported with absolute and rela-
tive frequencies and quantitative variables with mean (95% CI). Normal distribution of quantitative variables 
was assessed by the Shapiro-Wilk test. For comparative analyses, serum biomarkers were compared using the 
Student t-test for normally-distributed variables and using the Mann-Whitney test for non-normally-distributed 
variables.
Ethical consideration. The study was carried out in accordance with L.1123-6 article of the French Health 
Code. The study protocol was approved by the local ethics committee (Comité consultatif de Protection des 
Personnes en Recherche Biomédicale d’Île-de-France 1). Informed written and oral consent was obtained from all 
participants.
Sources of funding and role of funders. The study was funded by Assistance Publique-Hôpitaux de 
Paris (project n°MERRI-AAP-2017-008). The funding source was not involved in the study design, data collec-
tion or interpretation, statistical analysis, manuscript preparation, or the decision to submit the manuscript for 
publication.
Results
Patients. Overall, 2,292 patients were consecutively screened, 37 met inclusion criteria and were prospec-
tively enrolled in the primary study. The full flow diagram was published12. Because for 3 patients, serum samples 
were not sufficient to perform at least 1 laboratory test, serum from 34/37 patients were analysed in the pres-
ent study. Mean (95% CI) age was 44.1 (40.0–48.1) years and mean LBP duration was 72.5 (53.0–91.9) months 
(Table 1).
Serum biomarkers of inflammation. Mean concentrations of serum markers of inflammation (IL-1β, 
IL-6, IL-8 and TNF-α) did not differ between the 2 groups (Table 2).
Serum biomarkers of redox status. Mean concentrations of serum markers of redox status (total thiols, 
advanced oxidation protein products and carbonyl groups) did not differ between the 2 groups (Table 2).
Serum biomarkers of cartilage degradation. Mean concentrations of serum markers of cartilage deg-
radation (Coll2-1 and Coll2-1NO2) did not differ between the 2 groups (Table 2).
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Discussion
In the present study, we did not find any differences in serum biomarkers of inflammation, redox status and car-
tilage degradation between cLBP patients with and without active discopathy.
With coefficients of variation ranging from 5 to 10% for spectrophotometric tests and less than 15% for immu-
noassays, our results are reliable. However, whether the techniques used were sensitive enough to detect systemic 
low-grade changes in inflammation or redox status in this population remains unknown. Because active disco-
pathy is associated with disc degeneration and because chondral plate degradation and type 2 collagen is found 
in the nucleus pulposus and chondral plates17, we anticipated an increase of Coll2-1 and Coll2-1NO2 level in the 
serum of patients with active discopathy18–20. The absence of changes in these biomarkers levels was unexpected. 
The absence of pro-inflammatory cytokines increase in the serum of patients with active discopathy was also 
surprising. However, consistently with our findings, Capossela and colleagues did not find any differences in the 
serum levels of various inflammatory mediators including IL-1β, IL-6 and TNF-α between people with LBP and 
pain-free volunteers21. Correlations between serum biomarkers of redox status and cartilage degradation and 
intervertebral disc disease and low back pain have not been described yet.
Also, whether LBP overall was associated with changes that might be masking smaller differences between 
patients with and without active discopathy remains unanswered. Values we found seemed different from the val-
ues reported in the general population. In previous studies, mean serum levels were 4.6 pg/ml for IL-1β, 18.3 pg/
ml for IL-6, 38.3 pg/ml for IL-8, 37.0 pg/ml for TNF-α22, 291.6 (39.9) µmol/l for total thiols23, 125.8 (40.6) µmol/l 
for advanced oxidation protein products23, 0.3 (0.0) nM/mg of proteins for carbonyl groups24, 125.1 (3.7) nmol/l 
Control (Modic 0) 
n = 21
Cases (Modic 1) 
n = 13 All patients n = 34 p-value*
Demographic characteristics of patients
   Age (years), mean (95% CI) 42.0 (37.6; 46.4) 47.4 (38.9; 56.0) 44.1 (40.0; 48.1) 0.23
   Body mass index (kg/m2), mean (95% CI) 23.4 (22.3; 24.5) 26.3 (24.4; 28.3) 24.5 (23.5; 25.6) 0.01
   Currently working (yes), n (%) 17 (81.0) 9 (69.2) 26 (76.5) 0.43
   Currently smoking (yes), n (%) 9 (42.9) 6 (46.2) 15 (44.1) 0.85
Characteristics of chronic low back pain
   Low back pain duration (months), mean (95% CI) 62.7 (41.4; 84.0) 88.2 (47.9; 128.5) 72.5 (53.0; 91.9) 0.24
   Low back pain intensity (0-100 mm VAS), mean (95% CI) 45.5 (34.1; 56.8) 47.6 (35.0; 60.2) 46.3 (38.2; 54.4) 0.79
   Quebec score (0-100), mean (95% CI) 30.8 (25.0; 36.5) 37.5 (29.4; 45.5) 33.3 (28.7; 37.9) 0.16
   Worst painful moment in the morning or at night and/or 
morning stiffness (yes), n (%) 7 (33.3) 8 (61.5) 15 (44.1) 0.11
Current treatments (yes), n (%)
   Painkillers 14 (66.7) 5 (38.5) 19 (55.9) 0.11
   Non-steroidal anti-inflammatory drugs 4 (19.1) 3 (23.1) 7 (20.6) 0.78
Table 1. Participants’ baseline characteristics. No missing data; 95% CI: 95% confidence interval. 
*Comparisons between Modic 0 and Modic 1 groups. Numbers in the brackets are 95% CI, unless otherwise 
indicated.
Biomarkers, mean (95% CI)
Control (Modic 0) 
n = 21
Cases (Modic 1) 
n = 13 All patients n = 34 p-value
Inflammation
   IL-1β (pg/ml)* 0.2 (0.1; 0.3) 0.2 (0.1; 0.3) 0.2 (0.1; 0.3) 0.466
   IL-6 (pg/ml)* 0.9 (0.5; 1.2) 0.8 (0.5; 1.1) 0.8 (0.6; 1.0) 0.906
   IL-8 (pg/ml)* 53.8 (−1.8; 109.3) 23.3 (0.0; 46.6) 41.8 (8.0; 75.6) 0.796
   TNF-α (pg/ml)* 3.2 (2.4; 3.9) 2.8 (2.3; 3.2) 3.0 (2.6; 3.5) 0.869
Redox status
   Total thiols (µM)**£ 333.7 (309.1; 358.3) 318.8 (271.4; 366.2) 327.8 (305.4; 350.3) 0.554
   Advanced oxidation protein products (µM)*$ 17.5 (5.0; 30.0) 12.8 (6.4; 19.2) 15.5 (8.1; 23.0) 0.246
   Carbonyl groups (nmol/mg of proteins)*# 1.0 (0.5; 1.5) 1.2 (0.8; 1.7) 1.1 (0.8; 1.4) 0.246
Cartilage degradation
   Col2-1 (nM)**§ 269.8 (239.2; 300.4) 241.6 (214.4; 268.8) 258.5 (237.7; 279.4) 0.150
   Coll2-1NO2 (pg/ml)*° 790.9 (549.8; 1032.0) 830.2 (577.6; 1082.8) 805.8 (638.4; 973.2) 0.472
Table 2. Serum biomarkers of inflammation, redox status and cartilage degradation. IL: interleukin; TNF: 
Tumor Necrosis Factor. *Comparisons between Modic 0 and Modic 1 groups using the Mann-Whitney 
test. **Comparisons between Modic 0 and Modic 1 groups using the Student t-test. The sample size varied 
depending on the parameter analysed. All these variations were due to low sample amount. £n = 33 patients (20 
controls and 13 cases). $n = 30 patients (18 controls and 12 cases). #n = 32 patients (19 controls and 13 cases). 
§n = 31 patients (18 controls and 13 cases). °n = 29 patients (18 controls and 11 cases). Numbers in the brackets 
are 95% CI, unless otherwise indicated.
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for Coll2-1 and 0.2 (0.1) nmol/l for Coll2-1NO225. However, direct comparisons between previously published 
data and ours is not possible because blood samples were collected in heterogeneous populations, in an unstand-
ardized manner and analyzed using different assays.
Even though inflammation is associated with disc activation, as suggested by the presence of infiltrated 
pro-inflammatory cells and the increased local expression of pro-inflammatory cytokines26,27, and may promote 
local redox status changes and cartilage degradation and the maintenance of an amplification loop between these 
3 elementary molecular pathways28, one can hypothesize that local changes in inflammation, redox status or 
cartilage degradation are too low grade to translate into detectable serum biomarkers. Unfortunately, there is no 
synovial fluid in intervertebral disc as in peripheral joints29. One possibility could be to perform intervertebral 
disc biopsy but this procedure is too aggressive and not ethical.
Some other reasons may explain our findings: active discopathy was limited to a single disc, our sample size 
was small and not specifically calculated for the purpose of the present study, and our population was originally 
selected to address another question12. Therefore, our study may have lacked power and external validity. Because 
data about variability in the different measures was not available before our study, the possibilities to power our 
study properly were initially limited. Therefore, the present study should be considered as an exploratory study 
to identify biomarkers sensitive to the disease condition and to provide variability in the different measures. For 
example, based on our findings, if the true difference in the case and control means is 30 nM for Coll2-1 serum 
level with a standard deviation of 55, we would actually need to study 54 cases and 54 controls to be able to reject 
the null hypothesis with a power of 80% and a type I error probability of 0.05. Inevitably the statistical power will 
be different for the other measures for the same given sample size. As another important limitation, our findings 
pertain to only men with cLBP. In the primary study, we took several steps to exclude people with coinciden-
tal bone fragility, which resulted in the exclusion of women12. Whether we would have had similar findings in 
women is unknown.
Conclusions
We did not find any differences in serum biomarkers between cLBP patients with and without active discopathy. 
Interpretation of our results is limited by the small sample size and the convenience sampling of our population. 
One plausible hypothesis is that local changes in elementary molecular pathways associated with active discopa-
thy do not translate into detectable serum biomarkers.
Data Availability
Full original protocol and dataset can be accessed upon request for academic researchers by contacting Associate 
Professor Christelle Nguyen (christelle.nguyen2@aphp.fr).
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